Wealth Enhancement Advisory Services LLC Raises Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Wealth Enhancement Advisory Services LLC lifted its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 55.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,945 shares of the biopharmaceutical company’s stock after buying an additional 38,850 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.05% of Sangamo Therapeutics worth $94,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SGMO. Mirae Asset Global Investments Co. Ltd. acquired a new position in Sangamo Therapeutics during the first quarter worth about $331,000. State Board of Administration of Florida Retirement System grew its holdings in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares during the period. Acadian Asset Management LLC increased its stake in Sangamo Therapeutics by 4.0% in the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Sangamo Therapeutics by 58.8% during the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after purchasing an additional 1,528,600 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Sangamo Therapeutics by 56.3% during the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 207,476 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $2.71 on Wednesday. The stock has a fifty day moving average of $1.24 and a two-hundred day moving average of $0.83. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.29 and a fifty-two week high of $3.18. The company has a market capitalization of $564.28 million, a price-to-earnings ratio of -1.96 and a beta of 1.10.

Analyst Ratings Changes

Several research firms have recently issued reports on SGMO. StockNews.com assumed coverage on Sangamo Therapeutics in a research note on Sunday, July 28th. They set a “sell” rating for the company. HC Wainwright raised their target price on shares of Sangamo Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, November 5th.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.